Cluis Corinne P, Burja Adam M, Martin Vincent J J
Concordia University, Department of Biology, 7141 Sherbrooke West, Montréal, Québec, Canada, H4B 1R6.
Trends Biotechnol. 2007 Nov;25(11):514-21. doi: 10.1016/j.tibtech.2007.08.008.
Coenzyme Q or ubiquinone (UQ) is a naturally occurring coenzyme formed from the conjugation of a benzoquinone ring and an isoprenoid chain of varying length. UQ-10, the main UQ species produced by humans, provides therapeutic benefits in certain human diseases, such as cardiomyopathy, when administered orally. Increased consumer demand has led to the development of bioprocesses for the commercial production of UQ-10. Up to now, these processes have relied on microbes that produce high levels of UQ-10 naturally. However, as knowledge of the biosynthetic enzymes and of regulatory mechanisms modulating UQ production increases, opportunities arise for the genetic engineering of UQ-10 production in hosts, such as Escherichia coli, that are better suited for commercial fermentation. We present the various strategies used up to now to improve and/or engineer UQ-10 production in microbes and analyze yields obtained in light of the current knowledge on the biosynthesis of this molecule.
辅酶Q或泛醌(UQ)是一种天然存在的辅酶,由苯醌环与不同长度的类异戊二烯链共轭形成。UQ-10是人类产生的主要UQ种类,口服时对某些人类疾病(如心肌病)具有治疗益处。消费者需求的增加促使了用于商业生产UQ-10的生物工艺的发展。到目前为止,这些工艺依赖于天然产生高水平UQ-10的微生物。然而,随着对生物合成酶和调节UQ产生的调控机制的了解不断增加,在更适合商业发酵的宿主(如大肠杆菌)中对UQ-10生产进行基因工程改造的机会也随之出现。我们介绍了迄今为止用于改善和/或改造微生物中UQ-10生产的各种策略,并根据目前关于该分子生物合成的知识分析了所获得的产量。